Insmed Incorporated (INSM) Cash Flow Statement

The OCF/NI ratio of 6.71 in Q2 2026 is an outlier, driven by a net loss that includes a large non-cash gain or one-time item, while operating cash burn remains substantial. Excluding Q2, the ratio averages around 0.8, indicating that net losses typically translate into slightly larger cash outflows. The zero SBC in Q2 2026, as noted in the income statement analysis, may have inflated the earnings beat but does not affect cash flow, highlighting the need to focus on cash burn rather than EPS.

The FCF margin of -22.3% in Q2 2026 is the least negative in the past year, but the absolute burn remains high, reflecting heavy investment in Brensocatib and commercial expansion. The trajectory shows a slight improvement from the -$294.2M burn in Q4 2025, but the company is still far from cash flow breakeven. Investors should monitor whether the revenue acceleration can eventually outpace the investment spend, as the current burn rate suggests ongoing reliance on external financing.

CapEx/Revenue spiked to 17.7% in Q4 2025, likely due to a one-time investment, but otherwise remains in the low single digits. This suggests that the company's growth is not constrained by physical capacity, but rather by R&D and commercial spend, which are expensed through operating cash flow. The low CapEx also means that depreciation is minimal, so the gap between net income and operating cash flow is driven primarily by working capital and non-cash charges like SBC.

The negative working capital changes in recent quarters, particularly -$64.2M in Q1 2026 and -$24.9M in Q2 2026, suggest that the company is building inventory or extending receivables, possibly due to inventory stocking at specialty pharmacies. This pattern can create artificial revenue spikes, as noted in the accounting nuances, and may not reflect true patient demand. The positive working capital contributions in mid-2025 were insufficient to offset the overall cash burn, and the volatility warrants close monitoring of collection and inventory trends.

The absence of shareholder returns is consistent with a company in heavy investment mode, prioritizing the development of Brensocatib and the commercialization of ARIKAYCE. The $15.0M acquisition outflow in Q2 2026, though small, indicates selective M&A activity. Given the persistent negative free cash flow, the company will likely need to raise additional capital, either through equity or debt, which could dilute existing shareholders.

The cumulative gap of $440M suggests that reported losses overstate the cash drain, but the company still consumed nearly $2B in cash from operations. This divergence is typical for a biotech with significant stock-based compensation, which is a non-cash expense but still dilutive to shareholders. The cumulative cash burn underscores the urgency of achieving positive operating cash flow, as the company's balance sheet remains strained with a debt/equity ratio of 1.04.